

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version 3.11 Revision Date: 09/28/2024 SDS Number: 1679983-00015 Date of last issue: 09/30/2023
Date of first issue: 05/17/2017

SECTION 1. IDENTIFICATION

Product name : Clesrovimab (Drug Substance/Product)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Clesrovimab	2429913-18-6	$\geq 10 - < 20$
Sucrose	57-50-1	$\geq 5 - < 10$

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : None known.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

delayed
Protection of first-aiders : No special precautions are necessary for first aid responders.
Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Chlorine compounds

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version 3.11 Revision Date: 09/28/2024 SDS Number: 1679983-00015 Date of last issue: 09/30/2023
Date of first issue: 05/17/2017

absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Clesrovimab	2429913-18-6	TWA	5000 µg/m ³ (OEB 1)	Internal
Sucrose	57-50-1	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : 6.0

Melting point/freezing point : Not applicable

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	Not applicable
Particle characteristics	:	
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Clesrovimab:

Acute oral toxicity : Remarks: Not classified due to lack of data.

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Clesrovimab:

Remarks : Not classified due to lack of data.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Clesrovimab:

Remarks : Not classified due to lack of data.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Clesrovimab:

Remarks : Not classified due to lack of data.

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

Components:

Clesrovimab:

Genotoxicity in vitro : Remarks: Not classified due to lack of data.

Genotoxicity in vivo : Remarks: Not classified due to lack of data.

Sucrose:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Clesrovimab:

Remarks : Not classified due to lack of data.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Clesrovimab:

Effects on fertility : Remarks: Not classified due to lack of data.

Effects on fetal development : Remarks: Not classified due to lack of data.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Clesrovimab:

Species : Rat
NOAEL : 300 mg/kg
Application Route : Intravenous
Exposure time : 13 Days

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

Remarks	:	No significant adverse effects were reported
Species	:	Rat
NOAEL	:	< 100 mg/kg
Application Route	:	Intramuscular
Exposure time	:	13 Days
Remarks	:	No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Components:

Clesrovimab:

Not applicable

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Sucrose:

Partition coefficient: n-octanol/water	:	Pow: < 1
--	---	----------

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Water	7732-18-5
Clesrovimab	2429913-18-6
Sucrose	57-50-1

California Permissible Exposure Limits for Chemical Contaminants

Sucrose	57-50-1
---------	---------

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard




Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "/" represents a chronic hazard, while the "0" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse)

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Clesrovimab (Drug Substance/Product)

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.11	09/28/2024	1679983-00015	Date of first issue: 05/17/2017

Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/28/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8